Neurodegeneration and the Brain Tumor Microenvironment. [corrected]

Area of Science:

• Neuroscience
• Oncology
• Biochemistry

Background:

• Malignant brain tumors cause destructive growth and neuronal cell death, sharing mechanisms with neurodegenerative diseases.
• Gliomas exploit neuronal glutamate signaling, particularly through the xCT antiporter (SLC7a11), for growth and chemoresistance.
• The xCT antiporter's role in glutamate release and the tumor microenvironment makes it a key target.

Purpose of the Study:

• To critically analyze the mechanisms of the xCT antiporter in malignant gliomas and the tumor microenvironment.
• To explore the relationship between xCT, glutamate signaling, and TRP channels in brain tumors.
• To identify potential therapeutic targets for modulating the brain tumor microenvironment.

Main Methods:

• Literature review and critical analysis of existing data on xCT antiporter function.
• Investigation of glutamate/cystine antiporter (xCT) mechanisms in glioma.
• Examination of the interplay between xCT, glutamate, reactive oxygen species (ROS), and transient receptor potential (TRP) channels.

Main Results:

• Excessive glutamate release via xCT confers chemoresistance and creates a neurotoxic tumor microenvironment.
• Reactive oxygen species (ROS) activate TRP channels, which can potentiate glutamate release.
• The xCT/glutamate system significantly impacts the tumor microenvironment, affecting host cells and cancer stem cells.

Conclusions:

• The xCT antiporter is central to malignant glioma progression and neurotoxicity.
• Understanding the xCT/glutamate-TRP channel axis is crucial for developing novel brain tumor therapies.
• Targeting xCT, potentially with compounds like sulfasalazine, warrants further investigation for glioblastoma treatment.